Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash from Investing Activities (2020 - 2023)

Historic Cash from Investing Activities for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to $51.5 million.

  • Cullinan Therapeutics' Cash from Investing Activities rose 27990.21% to $51.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $35.8 million, marking a year-over-year decrease of 8561.86%. This contributed to the annual value of -$136.3 million for FY2024, which is 48070.16% down from last year.
  • According to the latest figures from Q4 2023, Cullinan Therapeutics' Cash from Investing Activities is $51.5 million, which was up 27990.21% from -$43.0 million recorded in Q3 2023.
  • Over the past 5 years, Cullinan Therapeutics' Cash from Investing Activities peaked at $300.9 million during Q2 2022, and registered a low of -$154.6 million during Q2 2021.
  • For the 4-year period, Cullinan Therapeutics' Cash from Investing Activities averaged around -$3.4 million, with its median value being -$8.9 million (2020).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 139140.42% in 2021, then soared by 29460.78% in 2022.
  • Over the past 4 years, Cullinan Therapeutics' Cash from Investing Activities (Quarter) stood at $11.4 million in 2020, then plummeted by 238.65% to -$15.9 million in 2021, then tumbled by 80.37% to -$28.6 million in 2022, then surged by 279.9% to $51.5 million in 2023.
  • Its Cash from Investing Activities was $51.5 million in Q4 2023, compared to -$43.0 million in Q3 2023 and $12.1 million in Q2 2023.